Biohaven provides update from pivotal phase 2/3 trial with verdiperstat in amyotrophic lateral sclerosis (healy als platform trial)

New haven, conn. , sept. 29, 2022 /prnewswire/ -- biohaven pharmaceutical holding company ltd.
BHVN Ratings Summary
BHVN Quant Ranking